Takeda Oncology offices based in Boston, Massachusetts
Massachusetts-based biotechnology company ImmunoGen has granted pharmaceutical company Takeda exclusive rights to use its antibody-drug conjugate (ADC) technology to develop and commercialise cancer drugs.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Takeda, ImmunoGen, M&A, Kadcyla, cancer